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Abstract: In this paper, the role of mesoporous silica (MS) particle size in the stabilization of 
amorphous simvastatin (SVT) is revealed. For inhibiting recrystallization of the supercooled drug, 
the two MS materials (Syloid® XDP 3050 and Syloid® 244 FP) were employed. The crystallization 
tendency of SVT alone and in mixture with the MS materials was investigated by Differential 
Scanning Calorimetry (DSC) and Broadband Dielectric Spectroscopy (BDS). Neither confinement of 
the SVT molecules inside the MS pores nor molecular interactions between functional groups of the 
SVT molecules and the surface of the stabilizing excipient could explain the observed stabilization 
effect. The stabilization effect might be correlated with diffusion length of the SVT molecules in the 
MS materials that depended on the particle size. Moreover, MS materials possessing different 
particle sizes could offer free spaces with different sizes, which might influence crystal growth of 
SVT. All of these factors must be considered when mesoporous materials are used for stabilizing 
pharmaceutical glasses. 
Keywords: Simvastatin; amorphous pharmaceuticals; mesoporous silica; stabilization; 
recrystallization 
 
1. Introduction 
The poor aqueous solubility of active pharmaceutical ingredients (APIs) is one of the most 
challenging issues of modern pharmacy [1–3]. Currently, over 40% of marketed immediate-release 
oral dosage forms contain poorly soluble drugs [4,5]. One of the most efficient methods that can 
improve solubility of poorly soluble drugs is amorphization [6–8]. It has been many times reported 
that the transformation into amorphous form significantly increased the solubility of drug molecules 
in comparison with their crystalline counterparts [8,9]. These benefits, however, come at a risk. The 
high internal energy of amorphous solids, which, on the one hand, is the reason for their high 
solubility, on the other hand, makes amorphous materials thermodynamically unstable [10–14]. 
Thus, currently, much effort is being made to i) investigate physical stability of amorphous form of 
pharmaceuticals [15–17], ii) find effective methods leading to their stabilization [18–20], and iii) 
discover the molecular mechanisms responsible for the observed recrystallization inhibition  
[16,21–25]. 
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As has been recently proven, one of the very effective inhibitors for recrystallization of the 
amorphous APIs during the time of their storage, transportation, or manufacturing are mesoporous 
silica (MS) materials [17,26–28]. It is worth highlighting that MS materials seem to be ideal excipients 
for drug formulation. This is because they might very effectively stabilize amorphous APIs and they 
can also very effectively enhance their bioavailability [29]. A great example of a drug in which 
bioavailability has been effectively enhanced after preparation MS based formulation is fenofibrate 
[30]. In choosing an appropriate MS for drug formulation, it is important to check its degradability. 
This is mainly because the approved pharmaceutical products must not accumulate in the human 
body since it can lead to unpredictable side-effects [31]. It has been proven that various biodegradable 
MSs are characterized by different speeds of biodegradability. This is a huge advantage of MS, since 
it results in the possibility of tuning the material to the selected drug according to the targeted 
applications [32]. 
Usually, the improvement of an amorphous drug’s physical stability by MS is explained by one 
of two mechanisms: i) confinement of the API molecules inside the MS pores or ii) molecular 
interactions between functional groups of the API molecules and the surface of the stabilizing 
excipient [28,33,34]. It is worth noting that, in the case of the former mechanism, it is possible to reach 
even an eternal stabilization effect [35]. Such a situation might occur only when the pore diameter of 
the employed MS is smaller than the critical crystal nuclei of the API, as well as if all API molecules 
are incorporated inside the pores. When the drug molecules are present outside the MS pores, the 
stabilization is usually explained by the second mechanism [36,37]. MS materials can inhibit the 
recrystallization of disordered APIs through interactions between the functional groups of the drug 
molecules and those on the MS surface; this is mainly due to their large specific surface area, which 
is often larger than 300 m2/g [38]. It has to be pointed out that this stabilization mechanism has one 
limitation—it works only when amount of the MS is enough to host a few layers of API molecules. 
In other words, if the number of drug molecules exceeds the amount of drug that can be 
“immobilized” on the MS surface, this mechanism cannot work for the inhibition of drug 
recrystallization. To accurately determine the loading capacity of a drug on MS surface, one can 
employ the method found by Hempel et al. (2019), which is an extension of the principle proposed 
by Mellaertes et al. (2017) [39,40]. This method is based on quantification of the API fraction that has 
not been immobilized by the MS surface through the detection of a glass transition temperature by 
Differential Scanning Calorimetry (DSC). 
In both stabilization mechanisms mentioned above, pores size, pore-volume, and surface area of 
MS play crucial roles. Consequently, one can find plenty of information on how these parameters 
affect the physical stability of amorphous APIs [41–43]. Little is known, however, about how the 
physical stability of amorphous APIs is influenced by the particle size of MS. Thus, the main aim of 
this article was to investigate the effect of the particle size of MS on the physical stability of 
amorphous API. As a model drug, we chose simvastatin (SVT)—a commonly prescribed lipid-
lowering medication. This pharmaceutical is characterized by excellent permeability but exhibits 
poor, solubility-limited, bioavailability (5%) [44]. Therefore, there is a need to improve the solubility 
of this compound. Two MS materials with a brand name of Syloid® 244 FP (SYL244) and Syloid® 3050 
XDP (SYL3050) have been employed for stabilizing amorphous state of SVT. These materials are 
characterized by nearly the same pore size, pore-volume, and surface area (see Table 1) [45,46] but 
differ in particle size. SYL3050 has an order of magnitude bigger particles than SYL244. To examine 
the tendency toward recrystallization of SVT mixed with MS materials, time-dependent isothermal 
crystallization experiments were performed utilizing two different experimental techniques: 
Differential Scanning Calorimetry (DSC) and Broadband Dielectric Spectroscopy (BDS). The 
principles of BDS are comprehensively reviewed in the book edited by Kremer and Schönhals (2003) 
[47]. The utilization of this experimental technique to study molecular mobility and crystallization 
phenomena in pharmaceutical systems are explained in detail in Grzybowska et al. [48] as well as in 
the books edited by Rams-Baron and Descamps [49,50]. The principles of DSC have been discussed 
in detail in Watson et al. (1964) [51] and Höhne et al. (2003) [52]. The use of DSC in the investigation 
of the isothermal cold crystallization of amorphous APIs has been briefly presented in Szklarz et al. 
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and Kolodziejczyk et al. [13,53]. Since all performed experiments showed that particle size had a 
significant impact on the physical stability of supercooled SVT, we tried to find the molecular 
mechanism responsible for the observed recrystallization inhibition. 
2. Materials and Methods  
2.1. Materials 
Simvastatin (SVT) with purity higher than 99.3% and molecular mass Mw = 418.6 g/mol was 
purchased from Polpharma (Starogard Gdański, Poland). This pharmaceutical is described 
chemically as Butanoic acid, 2,2-dimethyl-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8- 
[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester. Syloid® XDP 
3050 (SYL3050) and Syloid® 244 FP (SYL244), with the detailed specification presented in Table 1, 
were received as a gift from Grace GmbH & CO. KG (Worms, Germany). All chemicals were used as 
received. 
Table 1. Surface chemistry characterization of SYL244 and SYL3050 [47,48]. 
MS name: BATCH/LOS: 
Surface area 
(m2/g) 
Average 
particle size 
(μm) 
Pore diameter 
(nm) 
Pore volume 
(mL/g) 
SYL244 1000320678 314 2.5–3.7 23 1.6 
SYL3050 1000298877 320 59 22.9 1.7 
2.2.  Sample Preparation 
In order to obtain the binary mixtures containing simvastatin and 9, 18, 27, 36, 45, and 50 wt. % 
of SYL3050 or SYL244 the right amount of ingredients was weighed and mixed in mortars for about 
10 min. Prior to each experiment, the simvastatin in the physical mixture was melted at 423 K and 
quenched. For DSC experiments the sample was vitrified in situ the machine (with the flow of N2 = 
60 mL/min and cooling rate = 20 K/min), while for dielectric and microscopic experiments, the 
melting procedure takes place at the hot plate in air conditions. Melted material that was placed 
between the stainless-steel plates of the capacitor (for BDS) or glassy plates (for the optical 
m i c r o s c op e )  w a s  c o o l e d  b y  a  c o l d  c o o p e r  p l a te  w i t h  a  r a t e  o f  c a .  6 0  K / m i n . 
2.3. Differential Scanning Calorimetry (DSC) 
Thermal properties of SVT alone and that with SYL244 or SYL3050 were examined by a Mettler–
Toledo DSC 1 STARe System (Columbus, OH, USA) equipped with an HSS8 ceramic sensor and 120 
thermocouples. The instrument was calibrated for temperature and enthalpy using indium and zinc 
standards. Melting point was determined as the onset temperature, whereas the glass transition 
temperature as the midpoint of the heat capacity increment. The samples were measured in an 
aluminum crucible (40 μL). During non-isothermal experiments, heating rate of 10 K/min was 
employed. Each non-isothermal experiment was repeated three times, while isothermal experiments 
were repeated twice. 
2.4.  Broadband Dielectric Spectroscopy (BDS) 
Molecular dynamics of SVT alone and with SYL244 or SYL3050 was measured with a 
Novocontrol GMBH Alpha dielectric spectrometer (Montabaur, Germany). Dielectric spectra were 
registered in a broad frequency range from 10−1 Hz to 106 Hz. During the dielectric experiments the 
sample was heated from 173 K to 298 K with a step of 5 K and from 330 K to 362 K with a step of 2 K. 
The temperature was controlled by a Quattro temperature controller with temperature stability better 
than 0.1 K. The systems were measured in a parallel-plate cell made of stainless steel (diameter of 20 
mm, and a 0.1 mm gap provided by silica spacer fibers). 
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2.5.  Optical Microscope 
Optical images of SVT alone and the mixtures with 9 wt. % of SYL3050 or 9 wt. % of SYL244 
were captured using an Olympus BX51 polarized microscope (Olympus America Inc., Melville, NY, 
USA) equipped with an Olympus SC30 camera and a halogen source light. Optical images were 
collected using an Olympus Soft Imaging Solutions GmbH 5.1 (Münster, Germany) (analysis getIT 
software) at UMPlanFI 10× objective and at 0.3 NA. All images were handled by Adobe Photoshop 
12 software (Adobe Systems, San Jose, CA, USA). 
3. Results and Discussion 
3.1. Isothermal Crystallization Studies Performed by DSC 
Isothermal crystallization of neat SVT and its mixture with 9 wt. % of SYL244 or SYL3050 was 
investigated using DSC at 363 K, which is higher than the glass transition temperature by 58 K. 
Figure 1a shows the representative results obtained during the time-dependent isothermal 
measurements. The DSC curves of neat SVT and system containing SVT and SYL3050 reveal the 
exothermic peak of isothermal crystallization. The temperatures for crystallization onset of neat SVT 
and that for the mixture with SYL3050 were nearly the same (there is ~6 min shift after MS inclusion). 
However, big difference was observed for the time required for complete crystallization. In the case 
of neat SVT, the recrystallization ended after 5 h, while the presence of SYL3050 extended this process 
to 8 h. Interestingly, the presence of the same amount of SYL244, which has a smaller particle size, 
inhibited crystallization. This result indicates that the particle size of MS might have a significant 
i m p a c t  o n  t h e  p h y s i c a l  s t a b i l i t y  o f  t h e  a m o r p h o u s  S V T . 
Based on data obtained from DSC, one can estimate the relative degree of the sample 
crystallization (αDSC) by utilizing the following formula: 
     =
∫
  
     
 
  
∫
  
     
  
  
 (1) 
where dH/dt is the rate of heat evolution. t0 and t∞ represent the time at which crystallization begins 
and ends, respectively. The time evolutions of αDSC, as determined from DSC experiments, are 
presented in Figure 1b. The kinetic curves were normalized by the maximal value of the αDSC, which 
was registered when crystallization has ended. After the isothermal step of DSC experiments, the 
samples were cooled down and reheated to confirm the degree of crystallinity. 
 
Figure 1. (a) Differential Scanning Calorimetry (DSC) traces of neat simvastatin (SVT) (black line), 
SVT + 9 wt. % of SYL3050 (green line), and SVT + 9 wt. % of SYL244 (red line) recorded during 
isothermal crystallization at 363 K (b) and corresponding relative crystallinity (αDSC). 
To properly describe the crystallization kinetics of the investigated samples under isothermal 
conditions, the Avramov model was employed [54]. In this approach, the dependence of αDSC, 
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together with its first derivative, is plotted versus ln t on the same axis. In coordinates αDSC against ln 
t, the inflection points in all cases appeared at α < 0.63, and induction times have been determined as 
8800 ± 100 s and 9150 ± 50 s for neat SVT and SVT + 9 wt. % of SYL3050, respectively. Finally, i.e., 
utilizing the value of t0, the correct Avrami–Avramov plots have been constructed (see Figure 2). 
From this plot, one can obtain the value of the characteristic time of the crystallization process (τcr) as 
the time corresponds to d(αDSC)’/[d(ln(t − t0))] peak maximum. The determined τcr for neat SVT and 
SVT + 9 wt. % of SYL3050 are equal to 55 ± 1 min and 107 ± 3 min, respectively. The change in τcr 
toward the larger value after addition of SYL3050 indicated improvement in physical stability of SVT 
in the presence of the MS. Of course, a much better stabilization effect has been reached after 
employment of the MS characterized by an order of magnitude smaller particle size than in case of 
SYL3050, what is reflected as lack of SVT re-crystallization. 
 
Figure 2. The Avrami–Avramov plot presenting a time evolution of relative crystallinity (αDSC) (full 
symbols) and its first derivative toward the natural logarithm of the time (shadowed symbols) of neat 
SVT (grey circles) and SVT + 9 wt. % of SYL3050 (green squares). 
Use of the Avramov model allows us to calculate another parameter, n, which is directly related 
to the nucleation dimensionality. Two methods are available to determine n. The first is based on 
employment the following equation: 
  =
( ( ))   
 
0.368
 (2) 
where (α(t))’max is a maximum value of the first derivative of the normalized degree of crystallization. 
The second approach of evaluation the Avramov parameter related to the nucleation dimensionality 
is based on drawing a tangent to the experimentally determined sigmoidal curve αDSC(ln(t − t0)) at t − 
t0 = τcr (see dashed lines in Figure 2). By determining the values of ln t1 and ln t2, which corresponds to 
the points of intersection of the tangent line with the horizontal straight lines, constructed at the limit 
values of αDSC, i.e., at 0 and 1, it is possible to establish the n parameter from the following formula: 
  =
 
ln    − ln   
 (3) 
The values of t0, ln t1, ln t2, (α(t))’max, τcr as well as n calculated using both equations are collected in 
Table 2. As can be seen, regardless of the employed method for determination of n value, the 
dimensionality of crystallization of SVT was reduced when SYL3050 was added to the drug. 
Table 2. Comparison of parameters estimated from Avramov model for kinetics of isothermal 
crystallization obtained from DSC measurements. 
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Sample: t0 (s) 
τcr 
(min) 
ln t1 ln t2 
n 
(Equation 
3) 
α(t)′ max 
n (Equation 
2) 
neat SVT 
8800 ± 
100 
55 ± 1 7.65 ± 0.02 
8.361 ± 
0.001 
3.8 ± 0.1 1.57 ± 0.09 4.3 ± 0.2 
SVT + SYL3050 9150 ± 50 107 ± 3 7.79 ± 0.04 9.33 ± 0.08 1.8 ± 0.1 0.73 ± 0.06 2.0 ± 0.2 
3.2. Isothermal Crystallization Studies Performed by BDS 
The second method employed to study the isothermal crystallization of neat SVT and its 
mixtures with MSs having two types of particle size was BDS. During the time-dependent dielectric 
experiments, the spectra of the complex dielectric permittivity ε*(ω) = ε′(ω) − iε″(ω) were investigated 
at specified time intervals of 300 s. By using dielectric spectroscopy, the crystallization process can be 
followed directly in both the real (ε′) and imaginary (ε″) parts of the complex dielectric permittivity, 
reflected by a decrease of the static permittivity (εs) and reduction of the loss peak intensity with time, 
respectively [49]. For our purpose, the real part of complex dielectric permittivity was selected for 
further analysis. The representative frequency dependences of ε′ measured during the time-
dependent dielectric experiments performed at T = 363 K for SVT + 9 wt. % of SYL3050 as well as SVT 
+ 9 wt. % of SYL244 are presented in Figure 3a,b. The neat SVT and that in the mixture with SYL3050 
recrystallized as evidenced by the registered decrease in the static permittivity (εs). Lack of drop in 
the εs observed during identical measurements performed on the SVT + 9 wt. % of SYL244 system  
(Figure 3b) indicated that the MS with smaller particle size was a better stabilizer for the amorphous 
SVT. This investigation agrees with the finding made during the DSC study where the particle size 
of MS was the important parameter for stabilizing amorphous SVT. After the isothermal dielectric 
experiments, the neat SVT and its mixture with SYL3050 were subjected to the DSC measurement to 
confirm that crystallinity of both samples reached 100%. 
Usually, the progress of crystallization is analyzed in terms of the normalized real permittivity 
(ε’N) defined as follows [55–57]: 
  
  ( ) =
  (0) −   ( )
  (0) −   (∞)
 (4) 
where ε′(0) is the initial static dielectric permi ivity, ε′(∞) is the long-time limiting value, and ε′(t) is 
the value at time t. The data normalized in this way and plotted versus time are shown in Figure 3c. 
 
Figure 3. (a) Dielectric spectra of the real parts of the complex dielectric permittivity during an 
isothermal crystallization of SVT + 9 wt. % of SYL3050 performed at 363 K, (b) dielectric spectra of the 
real parts of the complex dielectric permittivity collected during the time-dependent isothermal 
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experiment of SVT + 9 wt. % of SYL244 performed at 363 K, (c) normalized dielectric constants ε′N as 
a function of time from crystallization processes occurring at 363 K. 
Crystallization of SVT in the mixture with 9 wt. % of SYL3050 is delayed in comparison to that 
of the neat SVT. The entire crystallization process of the neat SVT and that in the mixture with 
SYL3050 required ca. one day and three days, respectively, at 363 K. Analysis based on the Avramov 
model revealed that the inflection points have appeared at α < 0.63, whereas the induction times have 
been determined as 13,600 ± 400 s and 29,750 ± 250 s for neat SVT and SVT + 9 wt. % of SYL3050, 
respectively. By utilizing the estimated values of t0, the Avrami–Avramov plot for each sample was 
constructed (Figure 4). Determined from the d(αDSC)’/[d(ln t − t0)] peak maximum, the characteristic 
time of the crystallization process (τcr) for neat SVT and that in the mixture with 9 wt. % of SYL3050 
are equal to 201 ± 12 min and 737 ± 28 min, respectively. 
 
Figure 4. The Avrami–Avramov plot presenting a time evolution of normalized real permittivity (ε’N) 
(full symbols) and its first derivative toward the natural logarithm of the time (shadowed symbols) 
of neat SVT (grey circles) and SVT + 9 wt. % of SYL3050 (green squares). 
The n values together with other parameters were determined in the same manner as described 
in the previous section are summarized in Table 3. The n value for the SVT in the mixture with 
SYL3050 is smaller than that for the neat SVT, which agreed with the results obtained from the DSC 
study. 
Table 3. Comparison of parameters estimated from Avramov model for kinetics of isothermal 
crystallization obtained from dielectric measurements. 
Sample:  t0 (s) τcr (min) ln1 ln2 
n (Equation 
3) 
α(t)max’ 
n (Equation 
2) 
neat SVT 13,600 ± 400 201 ± 12 8.71 ± 0.06 9.88 ± 0.02 2.34 ± 0.07 0.91 ± 0.01 2.48 ± 0.04 
SVT + 
SYL3050 
29,750 ± 250 737 ± 28 9.02 ± 0.08 11.67 ± 0.08 1.026 ± 0.003 0.488 ± 0.001 1.326 ± 0.001 
It is worth highlighting that the crystallization kinetics of SVT was characterized by totally 
different parameter values for two different experimental techniques [58]. The recrystallization 
during the BDS measurement was much slower than that in the DSC study. For example, t0 BDS for 
the SVT in the mixture was 3.25 times longer than t0 DSC. By employing the dielectric spectroscopy, 
one can also observe an increase in the value of τcr as well as decrease in the n parameter in 
comparison to the values determined from the DSC study. The described differences between 
crystallization kinetics of the same systems measured by different experimental techniques are 
natural and result from differences existing between the employed techniques. For example, samples 
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used for the both techniques had totally different geometry (see inserts in Figure 5). The sample 
thickness for the BDS study was 0.1 mm, which was much thinner than that in the DSC measurement. 
The difference in the sample thickness results in different heat flow, which may influence the 
crystallization kinetics [58]. During the dielectric studies, samples were placed between stainless-
steel electrodes, which inhibited their contact with air. A decrease in the specific surface area delays 
crystallization because nucleation is frequently initiated from the surface [59,60]. Also, in the case of 
DSC measurements, samples were heated and quenched at a rate of 20 K/min under a nitrogen 
atmosphere prior to the crystallization experiment, whereas those for BDS studies were melted in the 
air on a hot plate and quenched at a rate faster by four-times than that for the DSC study. Both the 
atmosphere and the cooling rate [61] influence the amorphous property. Dimension of crystal growth 
is also influenced by the sample geometry [59]. Thus, the smaller n values in the BDS study compared 
to those from the DSC study is natural observation. Nevertheless, it should be emphasized that, 
despite quantitative differences in the crystallization kinetics obtained by the two different 
experimental techniques, one can find qualitative similarities on effect of the presence of the MS 
material, that is, its stabilization effect against crystallization of SVT. Moreover, a more striking 
stabilization effect was observed for SYL244 relative to SLY3050 despite their almost equal surface 
area (~300 m2/g), pore size (~20 nm), and pore volume (~1.65 mL/g). Therefore, it seems essential to 
find the reason for the observed differences in the stabilization of supercooled SVT. To achieve this 
goal, we were looking for the differences in the thermal properties and molecular dynamics of these 
compositions. 
 
Figure 5. Comparison of the time evolutions of normalized real permittivity (ε’N) and relative 
crystallinity (αDSC) as well as its first derivatives toward the natural logarithm of the time of neat SVT 
(grey circles) and SVT + 9 wt. % of SYL3050 (green squares). 
3.3. Loading Capacity of MSs for SVT 
To investigate how the MS materials, possessing different particle sizes, influence the thermal 
properties of SVT, both physical mixtures (i.e., samples containing crystalline API) and quenched 
samples (i.e., samples containing amorphous API) have been investigated non-isothermally through 
DSC. Figure 6a presents the DSC thermograms obtained during the sample heating with a rate equal 
to 10 K/min. As can be seen, neither the melting temperature of SVT nor its glass transition has been 
significantly modified after the inclusion of MS materials. The melting temperature of neat SVT, 
determined as the onset of the registered melting endotherm, is equal to 413 K. Mixtures containing 
SVT and 9 wt. % of SYL244 or SYL3050 are characterized by Tm equal to 412 K. After the quenching 
of all samples, the reheating DSC curves were acquired. As can be seen in Figure 6b, the thermogram 
of each sample reveal one step-like thermal event corresponding to glass transition of SVT. The Tg 
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midpoints of neat SVT, SVT + 9 wt. % of SYL244, and SVT + 9 wt. % of SYL3050 have the same value 
that is equal to 305 K, when heated at a rate 10 K/min. 
 
Figure 6. DSC thermograms of (a) crystalline and (b) amorphous SVT (grey lines), SVT + 9 wt. % of 
SYL3050 (green lines), and SVT + 9 wt. % of SYL244 (red lines). 
After the inclusion of MS material to SVT, the value of its ΔCp decreased. In the ideal case in 
which SVT molecules would not interact with the surface of MS, the value of ΔCp of the mixture 
should have linear relationship with the amount of SVT. When, however, some interactions between 
the drug and surface of MS exist, the decrease of ΔCp is larger than expected. Recently, Hempel et al. 
showed that by measuring the ΔCp value of various concentrations of a system containing drug and 
MS material, it is possible to estimate the monomolecular loading capacity of the drug on the surface 
of MS [41]. A series of samples possessing various concentrations of MS and SVT have been prepared 
and investigated in the same manner. The concentration dependences of ΔCp of SVT are presented in 
Figure 7. 
 
Figure 7. Linear extrapolation of the obtained ΔCp as a function of drug load. 
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By extrapolating a straight line describing the concentration dependence of ΔCp of both SVT + 
SYL244 and SVT + SYL3050 systems to zero, the monomolecular loading capacity values were 
determined. The amount of MS materials required to stabilize all SVT molecules on their surface was 
equal to 84.3 wt. % and 83.4 wt. % for SYL244 and SYL3050, respectively. Lack of significant 
discrepancies between these values proved that the employed MS materials interacted similarly with 
SVT. Therefore, considering these results, it is difficult to explain the dramatic difference in the 
stabilization effect of MS for the amorphous SVT by their loading capacities. 
3.4. Effect of MS Materials on the Molecular Mobility of Supercooled SVT 
Since no significant differences in loading capacities have been found between two MS materials, 
the following questions arise: Is the observed difference in SVT stabilization by MS materials 
possessing different particle size associated with some modifications in dynamics of the drug 
molecules? Is there any difference in the τα(T) of SVT when different MSs are employed? Or does the 
inhibition of the secondary relaxation processes play a crucial role? To answer these questions, 
molecular dynamics of the neat SVT and the systems containing SVT + 9 wt. % of SYL3050 and SVT 
+ 9 wt. % of SYL244 were evaluated by means of BDS. Representative dielectric loss spectra, which 
were measured above the samples glass transition temperatures, are presented in Figure 8a,c,d. As 
can be seen at this temperature region, the spectra of all investigated samples exhibit two features—
the dc-conductivity related to translational motions of ions and the structural (α) relaxation process 
associated with the cooperative rearrangement of the entire molecules. The α-relaxation mode always 
shifts toward higher frequencies with increasing temperature, indicating an increase in global 
mobility of the systems. 
 
Figure 8. Dielectric loss spectra of (a) neat SVT, (c) SVT + 9 wt. % of SYL244, and (d) SVT + 9 wt. % of 
SYL3050 collected above their respective Tgs upon heating. In panel (b), activation plots are 
constructed for the tested compounds with gray circles, red triangles, and green squares referring to 
temperature dependences of α-relaxation times for neat SVT, SVT + 9 wt. % of SYL3050, and SVT + 9 
wt. % of SYL244, respectively. The solid lines are the fitting results by the Vogel−Fulcher−Tammann 
(VFT) equation. 
From the analysis of dielectric loss spectra registered at supercooled liquid state, the temperature 
dependences of structural relaxation time (τα(T)) of all investigated samples were determined (see 
Pharmaceutics 2020, 12, 384 11 of 20 
 
Figure 8b). To obtain the value of τα at various temperature conditions, we fitted the experimental 
data by the Havriliak–Negami (HN) function. The empirical HN approach with the dc-conductivity 
term is given by the following formula [62]:  
 ∗( ) =    +
∆ 
[1 + (     ) ] 
+
   
    
 (5) 
where ε∞ is the high-frequency limit permittivity, ε0 denotes the permittivity of vacuum, Δε is 
dielectric strength, ω is equal to 2πf, τHN is the HN relaxation time, and a and b represent symmetric 
and asymmetric broadening of the relaxation peak. Employing the fit parameters determined above, 
we finally calculated the values of τα as 
   =      =    [sin (
   
2 + 2 
)] 
 
 [sin (
   
2 + 2 
)]
 
  (6) 
In the supercooled liquid region, the temperature evolution of τα usually shows non-Arrhenius 
behavior. Thus, to properly described τα(T) dependences of neat SVT and its mixture with 9 wt. % of 
SYL244 or SYL3050 we employed the Vogel−Fulcher−Tammann (VFT) equation that is expressed as 
follows [63–65]: 
   =   exp (
   
  −   
) (7) 
where τ∞, T0, and B are fitting parameters. Parameter τ∞ is a pre-exponential factor denoting the upper 
limit of temperature for τα, which is correlated to vibrational frequency (∼10–11 to 10–14 s). T0 is the 
Vogel temperature, which correspond to the state with infinite relaxation time, and D denotes 
deviation from the Arrhenius model. Extrapolating the VFT fits to temperature at which τα = 100 s, 
the Tg values of all the samples have been estimated to be 303 K. The glass transition temperatures 
determined by this method are in good agreement with that obtained from calorimetric studies (TgDSC 
HR =10 K/min = 305 K—see Figure 6). From the VFT fits, we also calculated the value of fragility parameter, 
mp, for all investigated samples. This parameter is a measure of deviation the τα(T) dependence from 
the Arrhenius behavior, and is defined as [66] 
   =
  log   
 (
  
  )
 
    
 (8) 
The typical values of the fragility parameter are between 50 and 100 [22,67,68]. The higher the fragility 
value, the more fragile the liquids. The mp parameter is considered to help predict the physical 
stability of amorphous pharmaceuticals because it has been implied that strong materials are more 
stable than the fragile ones [61,69]. However, the addition of MS did not have much of an impact on 
mp (Table 4); therefore, the difference in the crystallization behavior cannot be explained by the 
fragility. Thermodynamic parameters for each amorphous material are collected in Table 4. As can 
be seen, 9 wt. % of the used MS materials do not significantly modify the temperature evolution of 
τα of SVT, and consequently, no explanation of the observed stabilization has yet been found. 
Table 4. Comparison of the obtained based on the dielectric data values of Tg, mp and fitting 
parameters from the VFT for neat SVT, SVT + SYL3050, and SVT + SYL244. 
Sample: Tg (K) log τ∞ T0 (K) BT0 mp 
SVT 303 −15.68 ± 0.13 244.01 ± 0.89 2386 ± 51 91 
SVT + SYL3050 303 −15.23 ± 0.11 246.23 ± 0.77 2240 ± 42 93 
SVT + SYL244 303 −15.18 ± 0.16 247.64 ±1.13 2183 ± 54 94 
To check if the shape of the structural relaxation peak of SVT remains constant in the whole 
examined temperature range, as well as what impact on it have the employed MS excipients, a so-
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called master plot has been constructed for each sample (see Figure 9a–c). To obtain the master plot, 
dielectric spectra taken from 302 K to 350 K was shifted to superimpose on the reference spectrum at 
314 K. The master plots show that the shape of the α-relaxation of SVT is invariant to the temperature 
changes, and the parameter βKWW for all spectra is the same. The value of the βKWW parameter of SVT, 
which describes the breadth of its structural relaxation loss peak, was determined by fitting the α-
peak at a temperature T = 314 K through the one-side Fourier transform of the 
Kohlrausch−Williams−Wa s (KWW) function [70]. This procedure gives a value of βKWW equal to 0.60, 
0.59 and 0.58 for neat SVT, SVT + 9 wt. % of SYL3050, and SVT + 9 wt. % of SYL244, respectively. It 
should be mentioned that the value of βKWW may vary within the 0–1 range. This parameter 
approaches 1 if the α-relaxation peak is narrow and symmetric and corresponds to the Debye case; 
however, when its value is approaching 0, the structural relaxation process is broad and asymmetric 
[47]. The βKWW might be correlated with crystallization tendency of amorphous materials [71]. It has 
been suggested that the physical stability of amorphous materials stored at similar relaxation times 
(τα) should decrease as βKWW increases. Based on this assumption, the physical stability of SVT should 
not be improved after the addition of MS, although the difference in βKWW is only marginal.  
According to the recent study by Paluch et al., anticorrelation between the width of the α-loss 
peak and polarity of the molecule, van der Waals glass formers with a broad α-loss peak (i.e., a small 
value of βKWW) should exhibit a low value of the dielectric strength (Δεα) [72]. SVT with βKWW = 0.6 and 
Δεα = 8.9 follows well this anticorrelation similarly to chloramphenicol (βKWW = 0.8, Δεα = 55) [73], 
MD20 (βKWW = 0.76, Δεα = 39) [74], azithromycin (βKWW = 0.52, Δεα = 1.2), or roxithromycin (βKWW = 0.62, 
Δεα = 1.6) [75] (see panel Figure 9d). 
 
Figure 9. (a–c) The master plot dielectric loss spectra of SVT + 9 wt. % of SYL3050, neat SVT, and SVT 
+ 9 wt. % of SYL244 formed by horizontal shifting of spectra to overlap the reference one. The dashed 
lines represent the KWW fit to the α-peak at 314 K with βKWW = 0.6, 0.59, and 0.58 for neat SVT, SVT + 
9 wt. % of SYL3050 and SVT + 9 wt. % of SYL244, respectively. (d) Dielectric strength Δε(Tg) as a 
function of the fractional exponent βKWW in the Kohlrausch-Williams-Watts function, taken from the 
reference 76. 
3.5. Effect of MS Materials on the Molecular Mobility of Glassy SVT 
In the glassy state, where the structural – α – relaxation becomes too slow to be experimentally 
observed, it is possible to monitor faster secondary relaxation processes associated with the local 
(inter- or intramolecular) motions [76]. It has been many times reported that this kind of motion might 
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be responsible for the crystallization of amorphous materials. The best examples of APIs in which 
secondary relaxations play a crucial role in physical stability are celecoxib and sildenafil [77,78]. To 
investigate how the MSs materials affect the secondary relaxation of SVT, the dielectric spectra at 
temperatures 173–293 K have been measured utilizing BDS. Representative spectra for neat SVT, SVT 
+ 9 wt. % of SYL244, and SVT + 9 wt. % of SYL3050 are shown in Figure 10a,c and d. 
 
Figure 10. The dielectric loss spectra of (a) neat SVT, (c) SVT + 9 wt. % of SYL244, and (d) SVT + 9 wt. 
% of SYL3050 registered at temperatures below Tg. (b) Selected spectrum of neat SVT with two well-
visible secondary relaxation processes β and γ. 
Two secondary relaxations (β and γ) were observed for both the neat SVT and that in mixtures 
with SYL244 or SYL3050. Both modes move toward higher frequencies with increasing temperature, 
indicating an increase in molecular mobility. To determine the values of τβ and τγ, the spectra of each 
sample have been fitted by two Cole−Cole (CC) functions. The example of the performed fi ing 
procedure is presented in panel b of Figure 10. It is worth recalling that the CC function is a special 
case of the HN function (Equation (5)) in which the b parameter is fixed at 1. As Figure 11 presents, 
in the glassy state of SVT, both τβ(T) and τγ(T) exhibit a linear dependence, and consequently can be 
well described by the Arrhenius equation: 
  ( ) =   exp (
  
  
) (9) 
where R is the gas constant, τ∞ is the pre-exponential factor, and Ea is an activation energy. The 
obtained values of Ea are collected in Figure 11. However, this analysis revealed that the stabilization 
effect (exerted) by MS, especially SYL244, cannot be explained by the secondary relaxation as it does 
not modify the γ-relaxation and the fact that it barely changes the dynamics of β-process of SVT. 
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Figure 11. The relaxation map of neat SVT (gray points), SVT + 9 wt. % of SYL244 (red points), and 
SVT + 9 wt. % of SYL3050 (green points). The Vogel–Tammann–Fulcher (VTF) equation was applied 
to describe structural relaxation times, while the temperature dependences of secondary relaxation 
times were fitted to the Arrhenius equation. 
3.6. Mechanism of SVT Stabilization with MS Materials  
Crystallization of the SVT should be inhibited if it is strongly adsorbed on the surface of MS. In 
fact, the adsorbed SVT molecules did not exhibit even the glass transition behavior. However, it was 
obviously not enough to explain the stabilization mechanism. Extensive BDS and DSC analysis 
revealed that many parameters to describe macroscopic thermodynamic and dynamic properties of 
the amorphous SVT remained almost the same after the addition of the MS materials. Moreover, 
despite significant difference in the stabilization effect between SYL244 and SLY3050, their influences 
on the amorphous properties of SVT was not obvious.  
We have added only 9 wt. % of MS to observe the drastic stabilization effect of the amorphous 
SVT. To provide sufficient loading capacity for SVT, a much larger amount of MS material, ca. 84 wt. 
%, is required. Consequently, the only remaining difference to explain observed stabilization effect 
is the difference in the particle size of the MS. 
Note that the stabilization effect was observed at 363 K, which is higher than the glass transition 
temperature by 60 K. Very high molecular mobility is expected for SVT at the experimental 
temperature for the crystallization study. A very small amount of stabilizers may influence the 
entirety of the materials because of the rapid diffusion of the SVT molecules. If the particle size is 
small, the exchange of the SVT molecules in the pores and those outside the particles should occur 
easily. If the particle size is large, the exchange may become difficult for the molecules located deep 
in the particles. This may explain the different stabilization effect of the two MS materials with 
different particle size. 
The global crystallization observed through X(t) (i.e., αDSC(t) or ε’N(t)) consists of nucleation and 
crystal growth. By a dimensional analysis of three-dimensional nucleation having the nucleation rate 
N = L−3t−1 and the linear crystal growth rate V = Lt−1, one can describe the crystallization process using 
a characteristic time t0 = (NV3) −1/4 and a characteristic size ξ = (V/N)1/4. As explained by Descamps and 
Willart [79], the competition between the characteristic, natural length scale (ξ), and the real 
macroscopic size (L) of the system induces a change in the kinetic regime as discussed in references 
[79,80] and visualized in Figure 12. 
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Figure 12. The time evolution of crystallinity of neat SVT (circles), SVT + 9 wt. % of SYL3050 (squares), 
and SVT + SYL244 (triangles), which were obtained from dielectric studies and described in Section 
3.2, together with the schematic explanation of the stabilization mechanism by MS materials. Yellow 
dot, yellow patterned circles, and gray filled circles represent SVT nuclei, SVT crystals, and MS 
particles, respectively. 
Particles of SYL244 (MS that is characterized by smaller particle size than SYL3050) may limit 
the real size of the drug (L) more effectively than large particles of SYL3050. On the other hand, 
particles of SYL3050 can form a restriction in SVT space that is absent when SVT is alone. Such a 
modification in the sample size can affect both the time scale of the crystallization process and the 
expression of the kinetic law itself. Consequently, a dramatic slowing down of the SVT kinetic is 
expected after the reduction of L that is realized by the employment of MS materials. 
To verify the proposed hypothesis explaining the physical improvement of supercooled SVT 
after the inclusion MS materials, the optical microscopy was employed. The obtained optical images, 
with a scale bar equal to 50 μm are presented in Figure 13. Panels A–C present the row microscopic 
data, while panels D–E present improved images with adjustment of the contrast. As can be seen, the 
smaller the particle size, the more steric hindrance is generated (i.e., less free space for the sample 
crystal growth exists—compare the areas marked by the red circles in Figure 13E,F). It consequently 
leads to the reduction of drug connectivity and thereby loss of crystallization propagation pathways 
and an increase of the physical stability of SVT. 
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Figure 13. (A–C) The optical images, which were collected at 5× magnification, of neat SVT, SVT + 9 
wt. % of SYL3050, and SVT + SYL244 (the scale bars are equal to 50 μm). (D–F) The images from panels 
a–c with artificial contrast (the red circles represent the representative free areas of the SVT alone and 
in mixture with MS). 
4. Conclusions 
In this paper, we investigated the effect of two MS materials (SYL244 and SYL3050) on the 
physical stability of supercooled SVT. These MS materials differ from each other only by the size of 
particles. SYL3050 possesses particles that are an order of magnitude larger than SYL244. To 
investigate the kinetics of crystallization of both SVT alone and in mixture with the MS, two 
experiments—DSC and BDS—were employed. Despite the differences in the obtained crystallization 
kinetics resulting from the use of different research techniques, one could have observed the same 
stabilization trends. Neat SVT begins to recrystallize faster, and its crystallization kinetic curve is 
much steeper than after the inclusion SYL3050. Furthermore, in the case of the MS having a smaller 
particle size, a lack of sample recrystallization was noted. To find a molecular mechanism responsible 
for the observed improvement of physical stability of SVT, we performed a series of calorimetric and 
dielectric studies. The obtained results showed that neither thermal properties nor molecular 
dynamics are significantly changing after inclusion to SVT the MS material. Consequently, none of 
the known stabilization mechanisms can explain the observed inhibition of SVT recrystallization. The 
particle size effect on the stabilization was likely to be explained by difference in exchange process 
between entrapped and bulk drug molecules. Moreover, reduction in size of the free space for crystal 
growth might be partially responsible for the different stabilization effect. These additional factors 
should be considered as well when mesoporous materials are used for stabilizing pharmaceutical 
glasses in addition to the direct interaction between mesoporous materials and drug molecules. 
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